Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Clement

Showing results (421-430 of 444) with videos related to

Pageof 45
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 25, 2010
A prospective cluster-randomized trial to implement the Canadian CT Head Rule in emergency departmentsIan G Stiell, Catherine M Clement, Jeremy M Grimshaw, et al.
Neuro-Oncology|November 21, 2019
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin Van Den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Cellular and Molecular Life Sciences : CMLS|May 12, 2023
Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastomaDena Panovska, Pouya Nazari, Basiel Cole, et al.
Immunity|March 5, 2024
CD4<sup>+</sup> T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapyAmelie Franken, Michel Bila, Aurelie Mechels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Neuro-Oncology|July 2, 2020
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin van den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC TrialKaspar Draaisma, C Mircea S Tesileanu, Iris de Heer, et al.
Oncoimmunology|June 7, 2023
Trial watch: chemotherapy-induced immunogenic cell death in oncologyJenny Sprooten, Raquel S Laureano, Isaure Vanmeerbeek, et al.
BMJ (Clinical Research Ed.)|November 11, 2025
Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trialIan G Stiell, Monica Taljaard, Debra Eagles, et al.
The EMBO Journal|March 20, 2019
A protein quality control pathway regulated by linear ubiquitinationEva M van Well, Verian Bader, Maria Patra, et al.
Pageof 45

Showing results (421-430 of 444) with videos related to

Sort By:
Pageof 45
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 25, 2010
A prospective cluster-randomized trial to implement the Canadian CT Head Rule in emergency departmentsIan G Stiell, Catherine M Clement, Jeremy M Grimshaw, et al.
Neuro-Oncology|November 21, 2019
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin Van Den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Cellular and Molecular Life Sciences : CMLS|May 12, 2023
Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastomaDena Panovska, Pouya Nazari, Basiel Cole, et al.
Immunity|March 5, 2024
CD4<sup>+</sup> T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapyAmelie Franken, Michel Bila, Aurelie Mechels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Neuro-Oncology|July 2, 2020
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin van den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC TrialKaspar Draaisma, C Mircea S Tesileanu, Iris de Heer, et al.
Oncoimmunology|June 7, 2023
Trial watch: chemotherapy-induced immunogenic cell death in oncologyJenny Sprooten, Raquel S Laureano, Isaure Vanmeerbeek, et al.
BMJ (Clinical Research Ed.)|November 11, 2025
Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trialIan G Stiell, Monica Taljaard, Debra Eagles, et al.
The EMBO Journal|March 20, 2019
A protein quality control pathway regulated by linear ubiquitinationEva M van Well, Verian Bader, Maria Patra, et al.
Pageof 45